Identification and characterization of a human IL-10 receptor antagonist

Human Immunology

Volumn 74, Issue 1, 2013, Pages 28-31

  Naiyer, Mohammed Mumtaz ^a   Saha, Shipra ^a   Hemke, Vijayshree ^a   Roy, Somenath ^b   Singh, Shailza ^a   Musti, Krishnasastry V ^a   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b VIDYASAGAR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 10 RECEPTOR ANTAGONIST; RECOMBINANT INTERLEUKIN 10; STAT3 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; DRUG IDENTIFICATION; HUMAN; HUMAN CELL; LEISHMANIASIS; MACROPHAGE ACTIVATION; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTIGENS, CD40; ANTIPROTOZOAL AGENTS; BINDING, COMPETITIVE; CELL LINE; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HOST-PARASITE INTERACTIONS; HUMANS; INTERLEUKIN-10; LEISHMANIA DONOVANI; MACROPHAGES; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-10; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84870941399     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.09.002     Document Type: Article

References (16)

1. Nylén S., Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 2007, 28:378-384.
2. Kane M.M., Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001, 166:1141-1147.
3. Sato T., Terai M., Tamura Y., Alexeev V., Mastrangelo M.J., Selvan S.R. IL-10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011, 51:170-182.
4. Gautam S., Kumar R., Maurya R., Nylén S., Ansari N., Rai M., et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 2011, 204:1134-1137.
5. Murray H.W., Lu C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., et al. IL-10 in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002, 70:6284-6293.
6. Aït-Oudhia K., Gazanion E., Vergnes B., Oury B., Sereno D. Leishmania antimony resistance. what we know what we can learn from the field. Parasitol Res 2011, 109:1225-1232.
7. Purkait B., Kumar A., Nandi N., Sardar A.H., Das S., Kumar S., et al. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrob Agents Chemother. 2011, [Epub ahead of print].
8. Haldar A.K., Sen P., Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol International 2011, 2011:571242. 10.4061/2011/571242.
9. van Griensven J., Balasegaram M., Meheus F., Alvar J., Lynen L., Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010, 10:184-194.
10. Ji J.D., Kim H.J., Rho Y.H., Choi S.J., Lee Y.H., Cheon H.J., et al. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2. Rheumatology 2005, 44:983-988.
11. van der Spoel D, van Buuren AR, Apol E, Meulenhoff PJ, Tieleman DP, Sijbers AL, et al. Gromacs User Manual, 2001; Version 3.0. Nijenborgh, AG Groningen, The Netherlands.
12. Cornell W.D., Piotr C., Bayly I.B., Gould I.R., Merz K.M., Ferguson K.M.D.M., et al. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 1995, 117:5179-5197.
13. Weber-Nordt R.M., Riley J.K., Greenlund A.C., Moore K.W., Darnell J.E., Schreiber R.D. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem 1996, 271:27954-27961.
14. Finbloom D.S., Winestock K.D. IL-10 induces tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of STAT1a and STAT3 complexes in human T cells and monocytes. J Immunol 1995, 155:1079-1090.
15. Wehinger J., Gouilleux F., Groner B., Finke J., Mertelsmann R., Weber-Nordt R.M. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 1996, 394:365-370.
16. Williams L., Bradley L., Smith A., Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004, 172:567-576.